Qiagen N.V. (NYSE:QGEN) Receives $49.69 Consensus Target Price from Brokerages

Qiagen N.V. (NYSE:QGEN) has earned a consensus recommendation of “Hold” from the ten brokerages that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $49.6944.

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday. UBS Group lifted their price objective on Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Barclays set a $53.00 target price on Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. Cowen reiterated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Finally, Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st.

Qiagen Trading Up 0.5%

Shares of QGEN stock opened at $47.07 on Friday. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. The stock’s fifty day moving average is $46.44 and its two-hundred day moving average is $46.94. The firm has a market capitalization of $10.46 billion, a P/E ratio of 25.58, a PEG ratio of 2.39 and a beta of 0.68.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. During the same period in the prior year, the business earned $0.57 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Research analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC raised its stake in shares of Qiagen by 52.3% during the first quarter. Voya Investment Management LLC now owns 245,657 shares of the company’s stock valued at $9,845,000 after purchasing an additional 84,332 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Qiagen by 117.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock valued at $60,217,000 after buying an additional 675,498 shares during the period. Callan Family Office LLC acquired a new position in Qiagen during the 2nd quarter valued at about $304,000. US Bancorp DE raised its position in shares of Qiagen by 16.6% during the 2nd quarter. US Bancorp DE now owns 66,901 shares of the company’s stock worth $3,215,000 after buying an additional 9,544 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its stake in shares of Qiagen by 136.6% in the 2nd quarter. Moors & Cabot Inc. now owns 197,958 shares of the company’s stock worth $9,514,000 after acquiring an additional 114,289 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.